GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Ilyang Pharmaceutical Co 007570.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

6,770

+1.50%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Ilyang Pharmaceutical Co

Its shares trade on KRX under the ticker 007570.KS. It has been listed since 28 August 1974. In the fiscal year to 31 December 2025, it reported revenue of ₩272.42bn and net income of ₩6.90bn. At that date it held total assets of ₩457.33bn and shareholders' equity of ₩237.60bn.

Il-Yang Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Yongin, Gyeonggi-Do. The firm mainly manufactures and sells pharmaceutical products including prostatitis agents, anti-inflammatory drugs, diabetic agents, gastritis agents, and others. The firm also produces products including nourishing tonics and health supplements, among others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
28 Aug 1974

Leadership

Pay as last reported

  • Mr. Yu Seok JungPresident, Co-Chief Executive Officer, Director, since 2011
  • Mr. Dong Yeon KimCo-Chief Executive Officer, Vice Chairman, since 2024
  • Mr. Gyu Yeong ChoiManaging Director, since 2013
  • Mr. Seung Yeol GongNon-Executive Independent Director
  • Mr. Gwang Su JooNon-Executive Independent Director
  • Mr. Jung KimNon-Executive Independent Director
  • Yeon Chan JungIR Contact Officer, since 2021

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.